HARP - Harpoon Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Harpoon Therapeutics, Inc.

4000 Shoreline Court
Suite 250
South San Francisco, CA 94080
United States

Full Time Employees61

Key Executives

NameTitlePayExercisedYear Born
Dr. Luke B. EvninCo-Founder & ChairmanN/AN/A1963
Dr. Gerald McMahonPres, CEO & Director654.1kN/A1955
Dr. Holger Wesche Ph.D.Chief Scientific Officer419.47kN/A1968
Dr. Natalie R. SacksChief Medical Offer196.8kN/A1965
Ms. Georgia L. ErbezChief Financial OfficerN/AN/A1967
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536 for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Corporate Governance

Harpoon Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.